Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by allinenergy2on Aug 13, 2015 3:23pm
107 Views
Post# 24015979

You're Not a Lawyer CasusFortuitous, You're a LIAR

You're Not a Lawyer CasusFortuitous, You're a LIARYou keep OBFUSCATING your opinion or spin like it were the truth or fact, but it's just a spin.

Maybe you are a lawyer, and a good one at that.  Who knows, maybe you can eventually defend yourself, I don't know.

What I do know, is that I believe in the written word, not hearsay or green metal boxes.

I also know that charts have a say in how things trade, and I am quite convinced that Antibe will be doing another cheap 10 cent financing, but that's not the bad part.

The bad part is having to see you obfuscate how they failed in proving the safe dosage of a drug that is much safer than other NSAIDs that are on the market.  Just how much safer and effective is still to be decided, yet you've already called ATB-346 a poison.  

You are definitely a LIAR, and a good one at that in my opinion.

I'm not posting here to push anyone into buying ATE stock.  I don't pump or bash in order to fulfill my sell or buy orders.  I find this not only childish, but a manipulative plouy played by posters like yourself and others who feel the need to OBFUSCATE and manipulate what should be seen as the truth.

The truth does not LIE, unlike yourself.  The truth is that ATB-346, unless proven otherwise, has a dosage that seems effective at doses of 250 mg or less and is safe, whereas doses over 750 mg albeit effective are not safe.

ATB-346 is not a poison.  If it is, just tell us how many of the human patients other than the ones who were given over 750 mg doses fell ill, or suffered from lilver damage?

How many patients who were given doses of 250 mg or less suffered poisoning as you call it?

NONE......unless you wish to lie some more.  Good luck with your agenda.  It's not necessary, as you have the opportunity to buy quite a bit of shares at the going rate, but I'm not sure it will last as long as you think. 
Bullboard Posts